株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

高グレード神経膠腫:パイプライン製品の分析

High-Grade Glioma - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 271830
出版日 ページ情報 英文 253 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.53円で換算しております。
Back to Top
高グレード神経膠腫:パイプライン製品の分析 High-Grade Glioma - Pipeline Review, H1 2017
出版日: 2017年06月27日 ページ情報: 英文 253 Pages
概要

高グレード神経膠腫(HGG)は中枢神経系(CNS)の腫瘍で、脳・脊椎の悪性変換細胞より発症します。主な症状として、発達遅滞や頭痛・背痛、吐き気・嘔吐、めまい、歩行障害、視力低下、集中力低下、眠気、睡眠障害、不規則な食欲、麻痺・てんかんなどが挙げられます。主な治療法には、化学療法や放射線治療などがあります。

当レポートでは、世界各国での高グレード神経膠腫(グリオーマ)治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

高グレード神経膠腫(グリオーマ)の概要

治療薬の開発

  • 高グレード神経膠腫向けパイプライン製品:概要
  • 高グレード神経膠腫向けパイプライン製品:比較分析

各企業で開発中の高グレード神経膠腫治療薬

大学/研究機関で研究中の高グレード神経膠腫治療薬

パイプライン製品の概略

  • 治験段階の製品
  • 初期段階の製品

高グレード神経膠腫治療薬:開発中の製品の一覧(企業別)

高グレード神経膠腫治療薬:研究中の製品の一覧(大学/研究機関別)

高グレード神経膠腫治療薬の開発に従事している企業

  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline plc
  • Genentech, Inc.
  • Bayer AG
  • Virttu Biologics Limited
  • AngioChem Inc.
  • Stemline Therapeutics, Inc.
  • TAU Therapeutics, LLC
  • Tocagen Inc.
  • AROG Pharmaceuticals LLC

高グレード神経膠腫:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • ニンテダニブ
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • ANG-1005
  • ダブラフェニブ+トラメチニブ
  • 高グレード神経膠腫・肝臓移植向け遺伝子治療
  • 樹状細胞ワクチン
  • トシル酸ソラフェニブ
  • vocimagene amiretrorepvec + フルシトシンER(延長放出)
  • SL-701
  • ベシル酸クレノラニブ
  • ミベフラジル二塩酸塩
  • GDC-0084
  • HSV-1716
  • TBX-01
  • Toca

高グレード神経膠腫治療薬:パイプライン製品の最新動向

高グレード神経膠腫治療薬:開発が休止状態の製品

高グレード神経膠腫関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース(全2件)

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9468IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide High-Grade Glioma - Pipeline Review, H1 2017, provides an overview of the High-Grade Glioma (Oncology) pipeline landscape.

Highly grade gliomas (HGG) are tumors of the central nervous system (CNS) that arising from transformed cells of the brain and spinal cord. Symptoms include developmental delay, headaches, backaches, nausea and vomiting, dizziness, gait disturbances, impaired vision, lack of concentration, drowsiness, sleep disturbances, Dysregulated ap-petite, paralyses and seizures. Treatment includes Chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide High-Grade Glioma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for High-Grade Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The High-Grade Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for High-Grade Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 12, 11, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 2 molecules, respectively.

High-Grade Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of High-Grade Glioma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for High-Grade Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in High-Grade Glioma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates High-Grade Glioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for High-Grade Glioma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for High-Grade Glioma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding High-Grade Glioma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • High-Grade Glioma - Overview
    • High-Grade Glioma - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • High-Grade Glioma - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • High-Grade Glioma - Companies Involved in Therapeutics Development
    • Advenchen Laboratories LLC
    • AngioChem Inc
    • Arog Pharmaceuticals Inc
    • Astellas Pharma Inc
    • Athenex Inc
    • Bayer AG
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • BTG Plc
    • Cavion LLC
    • CBT Pharmaceuticals Inc
    • Concordia International Corp
    • DelMar Pharmaceuticals Inc
    • Ipsen SA
    • Millennium Pharmaceuticals Inc
    • Nektar Therapeutics
    • Novartis AG
    • Ono Pharmaceutical Co Ltd
    • Sanofi
    • Sorrento Therapeutics Inc
    • Sumitomo Dainippon Pharma Co Ltd
    • Targepeutics Inc
    • Tocagen Inc
    • ZIOPHARM Oncology Inc
  • High-Grade Glioma - Drug Profiles
    • AdRTSIL-12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • afatinib dimaleate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • alisertib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • apatinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bendamustine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMX-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cabazitaxel - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CBT-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Gliomas - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for High-Grade Glioma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • crenolanib besylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CYT-107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dabrafenib mesylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dianhydrogalactitol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DSP-7888 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • etirinotecan pegol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • flucytosine + TBio-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • flucytosine ER + vocimagene amiretrorepvec - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GB-13 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HSV-1716 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ipilimumab + nivolumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • irinotecan hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • irinotecan hydrochloride + TBio-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • irinotecan hydrochloride CR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KX-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mibefradil dihydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nivolumab - Drug Profile
      • R&D Progress
    • Oncolytic Virus for High-Grade Glioma and Melanoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • paclitaxel trevatide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • porfimer sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RRX-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sorafenib tosylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • High-Grade Glioma - Dormant Projects
  • High-Grade Glioma - Discontinued Products
  • High-Grade Glioma - Product Development Milestones
    • Featured News & Press Releases
      • May 11, 2017: Tocagen Presents Data at the American Society of Gene and Cell Therapy 20th Annual Meeting
      • Mar 16, 2017: Tocagen to Present Anti-Tumor Immune Response Data at 2017 Keystone Symposia
      • Feb 23, 2017: Tocagen Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Toca 511 & Toca FC in Recurrent High Grade Glioma
      • Nov 21, 2016: Tocagen Presents Updated Clinical and Preclinical Data at Scientific Meetings
      • Nov 10, 2016: Tocagen to Present Clinical and Preclinical Data at Upcoming Scientific Meetings
      • Oct 05, 2016: Tocagen Presents Updated Tumor Response Data for its Cancer-Selective Gene Therapy
      • Sep 30, 2016: Tocagen to Present Clinical and Preclinical Data at Two Scientific Meetings
      • May 13, 2016: Tocagen to Present Clinical and Preclinical Data at Three Scientific Meetings
      • May 03, 2016: Tocagen Presents Intravenous Toca 511 Clinical Data at the 84th AANS Annual Scientific Meeting
      • Apr 13, 2016: Tocagen to Present Data from Clinical Trials and Preclinical Programs at Four Scientific Conferences
      • Nov 23, 2015: Tocagen Presents Interim Data from Studies Evaluating Toca 511 & Toca FC at the Annual Meeting of the Society for Neuro-Oncology
      • Nov 18, 2015: Tocagen to Present Interim Results from Studies Evaluating Toca 511 & Toca FC at the Annual Meeting of the Society for Neuro-Oncology
      • Jul 09, 2015: FDA Grants Fast Track Designation to Tocagen's Toca 511 & Toca FC for Treatment of Recurrent High Grade Glioma
      • Jun 01, 2015: Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma
      • May 28, 2015: Cavion to Present Clinical Trial Data at ASCO
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for High-Grade Glioma, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • High-Grade Glioma - Pipeline by Advenchen Laboratories LLC, H1 2017
  • High-Grade Glioma - Pipeline by AngioChem Inc, H1 2017
  • High-Grade Glioma - Pipeline by Arog Pharmaceuticals Inc, H1 2017
  • High-Grade Glioma - Pipeline by Astellas Pharma Inc, H1 2017
  • High-Grade Glioma - Pipeline by Athenex Inc, H1 2017
  • High-Grade Glioma - Pipeline by Bayer AG, H1 2017
  • High-Grade Glioma - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • High-Grade Glioma - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • High-Grade Glioma - Pipeline by BTG Plc, H1 2017
  • High-Grade Glioma - Pipeline by Cavion LLC, H1 2017
  • High-Grade Glioma - Pipeline by CBT Pharmaceuticals Inc, H1 2017
  • High-Grade Glioma - Pipeline by Concordia International Corp, H1 2017
  • High-Grade Glioma - Pipeline by DelMar Pharmaceuticals Inc, H1 2017
  • High-Grade Glioma - Pipeline by Ipsen SA, H1 2017
  • High-Grade Glioma - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
  • High-Grade Glioma - Pipeline by Nektar Therapeutics, H1 2017
  • High-Grade Glioma - Pipeline by Novartis AG, H1 2017
  • High-Grade Glioma - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
  • High-Grade Glioma - Pipeline by Sanofi, H1 2017
  • High-Grade Glioma - Pipeline by Sorrento Therapeutics Inc, H1 2017
  • High-Grade Glioma - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
  • High-Grade Glioma - Pipeline by Targepeutics Inc, H1 2017
  • High-Grade Glioma - Pipeline by Tocagen Inc, H1 2017
  • High-Grade Glioma - Pipeline by ZIOPHARM Oncology Inc, H1 2017
  • High-Grade Glioma - Dormant Projects, H1 2017
  • High-Grade Glioma - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for High-Grade Glioma, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top